ndothelins (ETs) are a family of peptides that play important roles in regulating cardiovascular function. 1,2 ET-1, which causes potent and long-lasting vasoconstriction, is the major form produced by endothelial cells. 3 To date, 2 types of ET receptors have been identified: ET A is selectively activated by ET-1 , whereas ET B is selectively stimulated by sarafotoxin S6c. 1, 2, 4, 5 In vascular smooth muscle, ET A is the most abundant receptor with activation causing contraction in all vascular regions, irrespective of species. 1, 2 Although ET B can cause smooth muscle contraction in certain vascular beds, 6 activation of ET B is generally associated with vasodilation through the stimulated release of endothelial nitric oxide (NO). [7] [8] [9] ET A -mediated contraction of vascular smooth muscle may play an important role in the abnormal vasoreactivity associated with cardiovascular diseases, including coronary atherosclerosis and hypertension. 1,2,10 -12 Although impaired bioavailability of endothelial NO, which is associated with vascular diseases, causes a general increase in constrictor activity, it can also have some selective effects on ET activity. Decreased NO activity can cause increased production of ETs 11, [13] [14] [15] [16] [17] and enhanced constriction to these peptides by impairing ET B -mediated dilation. 7, 8, 18 The aim of the present study was to determine whether a prolonged decrease in NO activity could directly influence ET A receptormediated contraction in smooth muscle and, if so, to define the underlying mechanism(s).
Materials and Methods

Chemicals
Indomethacin, N -nitro-L-arginine methyl ester (L-NAME), phenylephrine, sarafotoxin S6c, BQ123, and U-46619 were obtained from Sigma (St Louis, Mo); the selective ET A receptor agonist ET-1 from Peptide International (Louisville, Ky); the TxA 2 /PGH 2 receptor antagonist S-Q29548 from ICN Pharmaceuticals (Costa Mesa, Calif); and cyclooxygenase (COX) substrate arachidonic acid from Calbiochem (La Jolla, Calif). The selective COX-2 inhibitor celecoxib was kindly provided by Pharmacia (St Louis, Mo). All other chemicals were of the highest commercially available quality.
Animal and Tissue Preparation
Wild-type (WT) and eNOS Ϫ/Ϫ mice (8 to 12 weeks) from The Jackson Laboratory (Bar Harbor, Me) were euthanized by CO 2 inhalation. This procedure was approved by the Institutional Laboratory Animal Care and Use Committee of The Ohio State University. The abdominal aorta, which contracts strongly to ET A receptor activation, 19 was rapidly excised and placed in ice-cold PSS (physiological salt solution; in mmol/L: NaCl 123, KCl 4.7, NaHCO 3 15.5, KH 2 PO 4 1.2, MgCl 2 1.2, CaCl 2 1.25, and D-glucose 11.5). Vessels were dissected free of adventitial fat and connective tissue. For tension measurements, aortic segments were cut into 1-mm vascular rings. For all other assays, aortas were cut open and the endothelial cells removed with a moist cotton swab. In some experiments, aortic segments were separated into adventitial and medial layers. All surgical procedures were performed under a binocular microscope.
Isometric Force Measurement
Isometric force measurement was performed as described previously. 19, 20 Briefly, the vascular ring was mounted between 2 tungsten wires, each with a diameter of 50 m, in a 37°C water-circulating tissue bath. One wire was stationary, whereas the other was connected to a force transducer (AE 801, Sensor One, Horten, Norway). Because the endothelium might release vasoactive mediators under basal conditions, most experiments were performed on endotheliumdenuded blood vessels. Therefore, unless stated otherwise, the endothelium was denuded from all aortic rings. This was achieved by rotating the rings around the tungsten wires while the passive tension was kept at 100 mg. 20 Thereafter, tissues were stimulated with 60 mmol/L K ϩ -PSS (equimolar replacement of NaCl with KCl) every 15 minutes, and the resting tension increased in a stepwise manner. After the equilibration, the resting tension was adjusted to approximately 300 mg, at which the maximal response to K ϩ was obtained.
Contraction evoked by an agonist was expressed as a percentage of the response to 60 mmol/L K ϩ . Concentration-effect curves to U-46619 or phenylephrine were generated by increasing the concentration of the agonists in half-log increments, once the contraction to the previous concentration had stabilized. Because responses to ET-1(1-31) were transient, contractions to the agonist were assessed by administering only a single concentration of the agonist. In all experiments, only a single curve (U46619, phenylephrine) or a single contraction [ET-1(1-31)] was analyzed on each aortic specimen. In addition, L-NAME (1 mmol/L), which did not affect ET A -mediated contraction in eNOS Ϫ/Ϫ mice, was added 20 minutes before the application of an agonist in WT mouse specimens. COX inhibitors (indomethacin, 3 mol/L; celecoxib, 3 mol/L) or the TxA 2 /PGH 2 receptor antagonist (SQ-29548, 1 mol/L) were applied 10 minutes before the application of an agonist.
Western Blot
Proteins (20 g for COX analysis, 40 g for ET A analysis) isolated from endothelium-denuded aortas were separated by electrophoresis on 10% SDS-PAGE and transferred onto a nitrocellulose membrane. After incubation with a monoclonal anti-COX-1 (Cayman Chemical, Ann Arbor, Mich; dilution: 1:1000), a polyclonal anti-COX-2 antibody (Cayman Chemical; dilution: 1:1000), or a monoclonal anti-ET A receptor antibody (BD Biosciences, Palo Alto, Calif; dilution 1:800), the nitrocellulose membranes were incubated with a horseradish peroxidase (HRP)-conjugated secondary antibody. The immunocomplex was detected with ECL plus kit (Amersham, Buckinghamshire, UK), and the band density was analyzed using a personal densitometer (Molecular Dynamics, Sunnyvale, Calif).
Immunofluorescence
Intact mouse abdominal aortic segment was frozen and cut into 5-m sections. Tissue sections were attached to glass slides and fixed with acetone. After treatment with primary antibody (1:100 dilution, sheep anti-ET A ; Alexis, San Diego, Calif), 21 tissues sections were incubated with anti-sheep Alexa flour-488 (Molecular Probes, Eugene, Ore). The fluorescent staining was detected using a Zeiss 510 laser scanning microscope equipped with a ϫ63 water immersion objective (NA 1.2). The image was analyzed by using Image J (NIH, Rockville, Md) software. The fluorescent intensity was expressed as the average pixel value, which is the sum of intensities of all the pixels in the area of selection divided by number of pixels.
Measurement of TXA 2 Metabolite TXB 2
Endothelium-denuded aortic strips (10 mm) were equilibrated in PSS at 37°C for 30 minutes. Thereafter, vessel strips were sequentially incubated in 150 L of PSS (baseline) and 100 nmol/L ET-1(1-31) or 10 mol/L PE in 150 L of PSS for 10 minutes, respectively. The PSS was then removed, snap frozen with liquid nitrogen, and stored at Ϫ80°C. TXB 2 was measured with an EIA kit (Amersham International), according to the instructions of the manufacturer.
Data Analysis
Data are expressed as meansϮSEM for n number of experiments, where n equals the number of animals from which blood vessels were studied. Statistical evaluation of the data were performed by Student's t test for either paired or unpaired observations. When more than 2 means were compared, ANOVA was used: either a 1-way ANOVA with Dunnett's post hoc test or 2-way ANOVA followed by Bonferroni's post hoc test (GraphPad 4 Software, San Diego, Calif). Values were considered to be statistically significant when P was Ͻ0.05.
Results
Contraction to ET A Receptor Activation Is Increased in eNOS ؊/؊ Aorta
The selective ET A receptor agonist ET-1(1-31) (10 to 100 nmol/L) caused contractions of endothelium-denuded abdominal aortas that were significantly increased in blood vessels from eNOS Ϫ/Ϫ compared with WT mice (Figure 1 ). In contrast, contractions to the selective ␣ 1 -adrenergic agonist phenylephrine (0.3 to 10 mol/L) or to the TxA 2 mimic U-46619 (30 to 300 nmol/L) were not significantly different between WT and eNOS Ϫ/Ϫ aortas ( Figure 1C and 1D). The selective ET B receptor agonist S6c (300 nmol/L) did not cause contraction of these abdominal aortas ( Figure 1B ). Similar to results observed in endothelium-denuded specimens, contractions to ET-1(1-31) (30 nmol/L) in aortas with intact endothelium were also increased in eNOS Ϫ/Ϫ compared with WT mice (92.9Ϯ6.9% and 48.3Ϯ6.8% of contraction to K ϩ , respectively, nϭ5, PϽ0.01; Figure 2 ). 
Expression of ET
Role of COX in Contraction to ET A Receptor Activation
Inhibition of COX by indomethacin (3 mol/L) or of TxA 2 / PGH 2 receptors by SQ-29548 (1 mol/L) significantly reduced the contraction evoked by 30 nmol/L ET-1(1-31) but did not affect contraction to 2 mol/L phenylephrine, which was of similar magnitude ( Figure 4A ). Indomethacin (3 mol/L) had a greater inhibitory effect against contractions to ET-1(1-31) in eNOS Ϫ/Ϫ compared with WT aortas. Indeed, after indomethacin, contractions to ET-1 were no longer increased and were actually decreased in eNOS 
COX Expression and Function in WT and eNOS
؊/؊ Aorta COX-1 was not detected in endothelium-denuded abdominal aortas from WT or eNOS Ϫ/Ϫ mice. In contrast, COX-2 expression could be clearly identified in endothelium- denuded abdominal aortas as well as medial smooth muscle layer but not in the adventitia ( Figure 5 ). In addition, expression of COX-2 was significantly increased in aortas from eNOS Ϫ/Ϫ compared with WT mice (2.8Ϯ0.2 fold, nϭ4, PϽ0.01) ( Figure 5 ). To directly assess the role of this increased COX-2 expression, the COX substrate arachidonic acid (10 or 30 mol/L) was administered to endotheliumdenuded abdominal aortas. Arachidonic acid caused contraction that was significantly greater in aortas from eNOS Ϫ/Ϫ compared with WT mice ( Figure 6A ). Contractions to arachidonic acid were inhibited by 3 mol/L indomethacin ( Figure 6B) .
Generation of the TxA 2 metabolite TxB 2 was determined in endothelium-denuded abdominal aortas from WT and eNOS Ϫ/Ϫ mice. ET-1(1-31) (100 nmol/L), but not the ␣ 1 - 
Discussion
Endothelin-mediated vasoconstriction contributes to abnormal vasoreactivity of cardiovascular diseases, including hypertension and atherosclerosis. 1,2,10 -12 This has been attributed to impaired bioavailability of endothelial NO, resulting in increased production of ETs and a generalized increase in vasoconstrictor responsiveness. 11, [13] [14] [15] [16] [17] The present study has identified an additional mechanism whereby the persistent loss of NO can selectively increase vasoconstriction to ET. ET A receptor activation caused contraction of abdominal aortas, which was selectively increased in aortas from eNOS Ϫ/Ϫ compared with WT mice. This increased contractility occurred despite a decreased expression of ET A receptors in aortic smooth muscle of eNOS Ϫ/Ϫ mice. However, expression of COX-2 was increased in the aortic smooth muscle of the eNOS Ϫ/Ϫ aortas, and the stimulated generation of COXderived contractile mediators dramatically amplified ET Amediated contraction. These results suggest that COX-2 metabolites may contribute to ET-induced vasoconstriction during the development of cardiovascular disease.
ET A receptors expressed on smooth muscle cells are primarily responsible for vasoconstriction mediated by ETs. 1,2 ET-1(1-31), a selective ET A agonist, caused contraction of endothelium-denuded abdominal aortas that was significantly increased in aortas from eNOS Ϫ/Ϫ compared with WT mice. However, contractions evoked by the ␣ 1 -adrenergic agonist phenylephrine or the TXA 2 analogue U-46619 were similar between aortas of eNOS Ϫ/Ϫ and WT mice. The ET B receptor agonist S6c (300 nmol/L) did not cause contraction of either blood vessel, which is consistent with the limited role of these receptors in mouse aortic contraction. 19 Therefore, the persistent loss of eNOS and NO activity is associated with a selective increase in contractile responsiveness to ET A receptor activation. Furthermore, the enhanced contraction of eNOS Ϫ/Ϫ aortas to ET-1(1-31) was observed in blood vessels with and without endothelium, indicating that it reflects altered responsiveness of vascular smooth muscle to ET A receptor stimulation.
Western blot and immunofluorescent techniques were used to assess ET A receptor expression. As expected, ET A receptors were detected in smooth muscle, but not in the endothelium, of abdominal aortas from WT or eNOS Ϫ/Ϫ mice. However, the expression of ET A receptors was surprisingly decreased in aortas from eNOS Ϫ/Ϫ mice. An explanation for this could be that the loss of NO may facilitate endothelial ET production, resulting in an increase in tissue or circulating ETs, which could then cause downregulation of smooth muscle ET A receptors. 14, 15, 17, 22 Indeed, vessels from deoxycorticosterone acetate salt hypertensive rats (which exhibit decreased endothelial NO activity) were reported to have elevated local or circulating ET level and decreased expression of ET A receptors. [23] [24] [25] [26] However, ET A receptor expression is also decreased in aortas from the spontaneously hypertensive rats, which appear to have normal vascular ET-1 content. 22, 23, 27 Moreover, in eNOS Ϫ/Ϫ mice, ET immunoreactivity in plasma was reported to be similar to that of control mice. 18 Therefore, downregulation of ET A receptors could also be mediated by mechanisms that are independent of increased local or circulating ET levels. Regardless of the underlying mechanism, decreased expression of ET A receptors in eNOS Ϫ/Ϫ mice would be expected to result in decreased rather than increased contraction to ET A receptor stimulation.
In aortas from WT mice, the COX inhibitor indomethacin or TXA 2 /PGH 2 receptor antagonist SQ-29548 inhibited contractions to ET-1(1-31) but did not affect responses to phenylephrine. These results suggested that contractions to ET A receptor activation are distinct from those induced by ␣ 1 -adrenergic activation in being mediated by COX-derived metabolites. In a similar manner to ET-11(1-31), the COX substrate arachidonic acid caused indomethacin-sensitive contractions of endothelium-denuded aortas that were significantly increased in blood vessels from eNOS Ϫ/Ϫ compared with WT mice. Therefore, we considered that increased COX activity might be responsible for the enhanced contraction to ET A receptor stimulation in eNOS Ϫ/Ϫ mice. This was confirmed by observations that ET-1(1-31) caused increased production of the TXA 2 metabolite TXB 2 in endotheliumdenuded abdominal aorta of eNOS Ϫ/Ϫ mice compared with WT mice and that indomethacin prevented the increased contraction of eNOS Ϫ/Ϫ aortas to ET-1 . In fact, after indomethacin, contractions to ET A receptor activation by ET-1(1-31) were decreased in aortas from eNOS Ϫ/Ϫ compared with WT mice. These results indicate that increased activity of COX in eNOS Ϫ/Ϫ aortas enables ET A receptor stimulation to overcome the decreased expression of the receptor, which would otherwise result in decreased contractility.
Two isoforms of COX, COX-1 and COX-2, have been identified in cultured vascular smooth muscle cells. 28, 29 In eNOS Ϫ/Ϫ mice, the selective COX-2 inhibitor celecoxib or TXA 2 /PGH 2 receptor antagonist SQ-29548 inhibited the contraction induced by ET-1(1-31) to a similar extent as the nonselective COX inhibitor indomethacin. This suggests that enhanced contraction to ET-1(1-31) in eNOS Ϫ/Ϫ mice is mediated through the COX-2 isoform. Indeed, endotheliumdenuded abdominal aortas from WT and eNOS Ϫ/Ϫ mice were found not to express COX-1, whereas COX-2 was found to be present in the medial layer of both blood vessels, with increased expression in aortas of eNOS Ϫ/Ϫ compared with WT mice. Therefore, these results identify an important role for COX-2 in ET A -mediated contraction of mouse abdominal aorta. They further demonstrate that increased expression of smooth muscle COX-2 mediates the enhanced contraction to ET A receptor activation in eNOS Ϫ/Ϫ abdominal aortas. Indeed, the TXA 2 analog U-46619 caused similar contractions in aortas from eNOS Ϫ/Ϫ and WT mice, suggesting that increased COX-dependent contractions to ET(1-31) and arachidonic acid reflected increased mediator production rather than altered sensitivity of TXA 2 /PGH 2 receptors.
Although COX-2 was originally identified as an inducible enzyme, subsequent studies have suggested that COX-2 is also constitutively expressed in some cell types. 28 -32 The results of the present study suggest that COX-2 is constitutively expressed by smooth muscle of mouse vasculature and can contribute to contractile responses. In addition, COX-2 expression and activity was increased in the smooth muscle of eNOS Ϫ/Ϫ mice. Similarly, smooth muscle expression of COX-2 is also increased in vascular diseases that are associated with impaired NO bioactivity, including atherosclerosis and diabetes. [33] [34] [35] [36] [37] Therefore, a persistent loss of NO activity might be a common event that results in increased expression of COX-2. Indeed, transcription of the COX-2 gene is dependent on the activity of factors such as nuclear factor B, 38, 39 which are sensitive to inhibition by endothelial NO. 40 -42 On the other hand, the exact mechanism for increased expression of COX-2 in eNOS Ϫ/Ϫ mice, and how decreased endothelial NO activity contributes to increased expression of COX-2 in these disease states, has not been defined. In patients with essential hypertension and in spontaneously hypertensive rats, ET-1 caused constriction of resistance blood vessels that was highly dependent on COXderived constrictor mediators. [43] [44] [45] This COX dependency was not observed in normotensive subjects and was not observed during ␣-adrenergic constriction. 43, 44 ET-1 or phenylephrine caused similar vasoconstrictor responses in hypertensive and normotensive patients. 44 However, after COX inhibition, constriction to ET-1 (but not phenylephrine) was dramatically reduced in hypertensive compared with normotensive individuals. 44 Therefore, as occurred in the present study, hypertensive-resistance arteries appear to have a selective reduction in sensitivity to ET-1, which is countered by a selective increase in the contribution of COX to the ET-1 response. Based on the present study, this may reflect decreased expression of ET A receptors countered by increased smooth muscle expression of COX-2. These results emphasize an important pathophysiological role of COX-derived metabolites in the vascular response to ET-1.
The findings of the present study also highlight important differences in the contribution of COX-2-derived metabolites to contractile responses between ET A and other receptors, including ␣ 1 -adrenoceptor and TXA 2 /PGH 2 receptor. The selective role of COX-2 in contractions to ET A receptor activation likely reflects differences in signaling pathways initiated by these distinct receptor species. These may involve steps that are essential to receptor-mediated PG or TXA 2 synthesis, including the activation of phospholipase A 2 , which leads to the release of arachidonic acid from membrane lipid pool, and the modulation of COX and other downstream enzymes, including TXA 2 synthase, which metabolize arachidonic acid to biologically active end products. 32, 33, 37 For example, ET A receptor can activate phospholipase A 2 and can also stimulate superoxide production via NADPH oxidase in vascular smooth muscle, 26, 46 which facilitates formation of lipid peroxides that are required for the activation of COX enzymes. 32, 33 In summary, smooth muscle contraction to ET A receptor stimulation was selectively increased in aortas from eNOS Ϫ/Ϫ compared with WT mice. This was associated with a decreased expression of ET A receptors, but increased expression of COX-2, in aortic smooth muscle cells of eNOS Ϫ/Ϫ compared with WT mice. Indeed, the increased contraction to ET A receptor stimulation was associated with increased production of the TXA 2 metabolite TXB 2 and was paralleled by increased contraction to the COX substrate arachidonic acid. Furthermore, contractile responses to stimulation of ET A receptors were selectively reduced by inhibition of COX-2 or TXA 2 /PGH 2 receptors. After COX inhibition, contractions to ET A receptor activation were no longer increased and were actually decreased in aortas from eNOS Ϫ/Ϫ compared with WT aortas. Therefore, these results suggest that increased expression of COX-2 mediates enhanced smooth muscle contraction to ET A receptor activation in eNOS Ϫ/Ϫ mouse abdominal aorta, overcoming a decreased expression of ET A receptors that would otherwise result in reduced contraction to the mediator.
